Takeda

News

ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data

Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.

News

UEGW delegates hear of strides forward in IBD treatment

Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.

News

Merck buys Silence and its siRNA pipeline for $1.3bn

Merck KGaA is slated to acquire UK-based Silence Therapeutics in a $1.3bn deal that would give it a late-stage drug for polycythemia vera.

News

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

Andy Plump to step down as Takeda's R&D chief

Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D in more than a decade of leadership at the division, has announced his retirement.

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data

UEGW delegates hear of strides forward in IBD treatment

Merck buys Silence and its siRNA pipeline for $1.3bn

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

Andy Plump to step down as Takeda's R&D chief

FDA clears Takeda, Protagonist's first-in-class PV drug

Dren Bio pockets $350m for rare blood cancer programme

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks